RATIONALE: The relationship between interstitial lung abnormalities (ILA) and exercise capacity has not been comprehensively evaluated. OBJECTIVES: To assess the validity of the 6-minute walk test in subjects with ILA, and to examine the association between ILA and 6-minute walk distance (6MWD). METHODS: Spearman correlation coefficients were used to assess the strength of the relationships between 6MWD and relevant measures of dyspnea, health-related quality of life, and pulmonary function in a cohort of 2,416 people who smoke from the COPDGene study. Unadjusted and adjusted linear and logistic regression models were used to assess the strength of the association between ILA and 6MWD. MEASUREMENTS AND MAIN RESULTS: In all subjects, and in those with ILA, 6MWD in COPDGene was associated with relevant clinical and physiologic measures. The mean 6MWD in COPDGene subjects with ILA was 386 m (SD, 128 m), and 82% and 19% of subjects with ILA had 6MWDs less than or equal to 500 and 250 m, respectively. ILA was associated with a reduced 6MWD in univariate (-30 m; 95% confidence interval, -50 to -10; P = 0.004) and multivariate models (-19 m; 95% confidence interval, -33 to -5; P = 0.008). Compared with subjects without ILA, subjects with ILA had an 80% and 77% increase in their odds to have a walk distance limited to less than or equal to 500 and 250 m, respectively. Although these findings were dependent on ILA subtype, they were not limited to those with COPD. CONCLUSIONS: Our study demonstrates that ILA is associated with measurable decrements in the 6MWD of people who smoke. Clinical trial registered with www.clinicaltrials.gov (NCT 00608764).
RATIONALE: The relationship between interstitial lung abnormalities (ILA) and exercise capacity has not been comprehensively evaluated. OBJECTIVES: To assess the validity of the 6-minute walk test in subjects with ILA, and to examine the association between ILA and 6-minute walk distance (6MWD). METHODS: Spearman correlation coefficients were used to assess the strength of the relationships between 6MWD and relevant measures of dyspnea, health-related quality of life, and pulmonary function in a cohort of 2,416 people who smoke from the COPDGene study. Unadjusted and adjusted linear and logistic regression models were used to assess the strength of the association between ILA and 6MWD. MEASUREMENTS AND MAIN RESULTS: In all subjects, and in those with ILA, 6MWD in COPDGene was associated with relevant clinical and physiologic measures. The mean 6MWD in COPDGene subjects with ILA was 386 m (SD, 128 m), and 82% and 19% of subjects with ILA had 6MWDs less than or equal to 500 and 250 m, respectively. ILA was associated with a reduced 6MWD in univariate (-30 m; 95% confidence interval, -50 to -10; P = 0.004) and multivariate models (-19 m; 95% confidence interval, -33 to -5; P = 0.008). Compared with subjects without ILA, subjects with ILA had an 80% and 77% increase in their odds to have a walk distance limited to less than or equal to 500 and 250 m, respectively. Although these findings were dependent on ILA subtype, they were not limited to those with COPD. CONCLUSIONS: Our study demonstrates that ILA is associated with measurable decrements in the 6MWD of people who smoke. Clinical trial registered with www.clinicaltrials.gov (NCT 00608764).
Authors: M R Shah; V Hasselblad; M Gheorghiade; K F Adams; K Swedberg; R M Califf; C M O'Connor Journal: Am J Cardiol Date: 2001-11-01 Impact factor: 2.778
Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King Journal: Am J Respir Crit Care Med Date: 2010-12-03 Impact factor: 21.405
Authors: David A Zisman; Marvin Schwarz; Kevin J Anstrom; Harold R Collard; Kevin R Flaherty; Gary W Hunninghake Journal: N Engl J Med Date: 2010-05-18 Impact factor: 91.245
Authors: Elizabeth A Regan; John E Hokanson; James R Murphy; Barry Make; David A Lynch; Terri H Beaty; Douglas Curran-Everett; Edwin K Silverman; James D Crapo Journal: COPD Date: 2010-02 Impact factor: 2.409
Authors: Jeffrey J Swigris; Frederick S Wamboldt; Juergen Behr; Roland M du Bois; Talmadge E King; Ganesh Raghu; Kevin K Brown Journal: Thorax Date: 2009-12-08 Impact factor: 9.139
Authors: George R Washko; Gary M Hunninghake; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; David A Lynch; John M Brehm; Katherine P Andriole; Alejandro A Diaz; Ramin Khorasani; Katherine D'Aco; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas Journal: N Engl J Med Date: 2011-03-10 Impact factor: 91.245
Authors: Mizuki Nishino; Stephanie Cardarella; Suzanne E Dahlberg; Tetsuro Araki; Christine Lydon; David M Jackman; Michael S Rabin; Hiroto Hatabu; Bruce E Johnson Journal: Eur J Radiol Date: 2015-02-07 Impact factor: 3.528
Authors: Anna J Podolanczuk; Elizabeth C Oelsner; R Graham Barr; Elana J Bernstein; Eric A Hoffman; Imaani J Easthausen; Karen Hinckley Stukovsky; Arindam RoyChoudhury; Erin D Michos; Ganesh Raghu; Steven M Kawut; David J Lederer Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405
Authors: William W Stringer; Janos Porszasz; Surya P Bhatt; Meredith C McCormack; Barry J Make; Richard Casaburi Journal: Chronic Obstr Pulm Dis Date: 2019-07-24
Authors: Samuel Y Ash; Rola Harmouche; Rachel K Putman; James C Ross; Alejandro A Diaz; Gary M Hunninghake; Jorge Onieva Onieva; Fernando J Martinez; Augustine M Choi; David A Lynch; Hiroto Hatabu; Ivan O Rosas; Raul San Jose Estepar; George R Washko Journal: Chest Date: 2017-05-12 Impact factor: 9.410
Authors: Coralynn Sack; Sverre Vedal; Lianne Sheppard; Ganesh Raghu; R Graham Barr; Anna Podolanczuk; Brent Doney; Eric A Hoffman; Amanda Gassett; Karen Hinckley-Stukovsky; Kayleen Williams; Steve Kawut; David J Lederer; Joel D Kaufman Journal: Eur Respir J Date: 2017-12-07 Impact factor: 16.671